Functional Brands Announces First Quarter 2026 Financial Results
Lake Oswego, Oregon--(Newsfile Corp. - May 18, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue grew to $1.65 million, up 3.5% from $1.59 million in the prior year period, reflecting continued momentum across the Company's brand portfolio. Gross profit
Household / Consumer / Cosmetics, Health
2026-05-18 8:00 AM EDT | Functional Brands Inc.
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their
Biotechnology, Pharmaceuticals, Health
2026-05-18 7:00 AM EDT | BioHarvest Sciences Inc.
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Dublin, Ireland--(Newsfile Corp. - May 18, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) (“Cosmo” or “the Company”) today announced the completion of patient enrolment in its Phase II clinical trial (EUCT number: 2023-506917-23-00) evaluating its novel investigational therapy, Rifamycin enema, for the treatment of distal ulcerative colitis (UC) and ulcerative proctitis. A total of 77 patients were enrolled at 24 clinical sites in Europe, reflecting strong
Healthcare and Hospitals, Health
2026-05-18 1:03 AM EDT | Cosmo Pharmaceuticals N.V.
UberDoc Health Technologies Announces Leadership Transition
Boston, Massachusetts--(Newsfile Corp. - May 15, 2026) - UberDoc Health Technologies Corp. (CSE: APPT) (FSE: 4KL0), a direct-pay healthcare marketplace connecting patients with board-certified specialists at transparent, upfront prices, today announced a leadership transition. Sean Kearney is departing as Chief Executive Officer, and founder Dr. Paula Muto has been named Interim Chief Executive Officer, as of Friday, May 15.
2026-05-15 8:00 PM EDT | UberDoc
Promino Announces Closing of Second Tranche of Private Placement
Burlington, Ontario--(Newsfile Corp. - May 15, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a performance nutrition company focused on clinically validated amino acid formulations, is pleased to announce that, further to its press releases dated March 13, April 22 and May 5, 2026, the Company has closed a second tranche (the "Second Tranche") of its private placement, issuing an aggregate of 13,437,000 unit
Food / Beverages, Sports, Health
2026-05-15 6:29 PM EDT | Promino Nutritional Sciences, Inc.
Restart Life Sciences Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio
Vancouver, British Columbia--(Newsfile Corp. - May 15, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an operational update regarding the strategic trademark licensing agreement previously announced on March 14, 2025. Over the past year, management has been actively working toward product launches leveraging the intellectual property (IP) and valuable business insights acquired under the agreement. Th
Technology, Biotechnology, Health
2026-05-15 4:00 PM EDT | Restart Life Sciences Corp.
ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026
Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments.
Healthcare and Hospitals, Health
2026-05-15 7:59 AM EDT | Adia Nutrition Inc.
AllStar Global Brands Announces Strategic Partnership with Riccione Femminile Calcio
Ontario and Riccione, Italy--(Newsfile Corp. - May 14, 2026) - AllStar Global Brands (OTCID: ALST) ("ASGB") is pleased to announce that an agreement has been reached to acquire a 60% ownership stake in Riccione Femminile Calcio for €50,000, marking the beginning of a long-term strategic partnership focused on developing women's football and international player pathways. As part of the agreement, ASGB will provide financial assistance, operational support, and access to d
Healthcare and Hospitals, Retail, Health
2026-05-14 10:37 AM EDT | AllStar Health Brands, Inc.
Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration(TM)
Reno, Nevada--(Newsfile Corp. - May 14, 2026) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a medical device company advancing regenerative medicine through its patented bioregenerative extracellular matrix platform, today unveiled a new defining identity: Architecting Bioregeneration™.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-14 8:30 AM EDT | Conexeu Sciences Inc.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-14 8:30 AM EDT | Red Light Holland Corp.
Custom Health Announces Appointment of Chief Financial Officer and Board of Directors and Shareholder Approval for Proposed Public Listing
Jason Nalewany has been appointed as Chief Financial Officer of Custom Health and, following the completion of the Arrangement, the Resulting Issuer. Jason will support both companies by providing public company compliance, financial reporting, capital allocation and long-term growth strategy. The Resulting Issuer and the operations of Custom Health will be supported by an experienced Board of Directors that bring deep expertise across healthcare, technology, capital markets and
Technology, Pharmaceuticals, Health
2026-05-14 7:00 AM EDT | Custom Health Holdings Inc.
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens
Biotechnology, Pharmaceuticals, Health
2026-05-14 7:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Highlights Granted Patent covers the design of VIVI Cap Smart™ across major international, growing market Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039 Company enters into f
Technology, Biotechnology, Pharmaceuticals, Health
2026-05-14 3:00 AM EDT | TempraMed Technologies Ltd.
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 25,347,133 common shares, representing 69.754% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in th
Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-13 8:41 PM EDT | Profound Medical Corp.
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceu
Biotechnology, Pharmaceuticals, Health
2026-05-13 5:32 PM EDT | BioHarvest Sciences Inc.
Mobile-health Network Solutions Enters into Non-Binding Strategic Memorandum to Facilitate Up to US$100 Million in Private Equity Funding for AI-Powered Healthcare Expansion
Singapore, Singapore--(Newsfile Corp. - May 13, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health platform, today announced that it has entered into a Letter of Memorandum with White Group Pte. Ltd. (Singapore) ("White Group") outlining a strategic collaboration to facilitate private equity funding of up to US$100 million to support MNDR's AI-powered healthcare expansion and digital health infrastr
2026-05-13 9:17 AM EDT | Mobile-health Network Solutions
Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting"). The special resolution approving t
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-13 9:12 AM EDT | Red Light Holland Corp.
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Pha
2026-05-13 8:00 AM EDT | BetterLife Pharma Inc.
RETRANSMISSION: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for ne
2026-05-13 8:00 AM EDT | DiagnosTear Technologies Inc.
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Colum
Biotechnology, Pharmaceuticals, Health
2026-05-13 8:00 AM EDT | BioHarvest Sciences Inc.